Previous 10 | Next 10 |
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2022 financial results after the market close on Monday, July 25, 2022. The Company will host a conference call the following morning, Tuesday, July 26, 2022, at 9:00 a...
Citing the recent challenges in the patient enrollment, the pharmacy chain operator Walgreens Boots Alliance (NASDAQ:WBA) announced the launch of its clinical trial business on Thursday to expedite the drug development process. Arguing that COVID-19 has exacerbated the difficulties in patient...
Medpace Holdings (NASDAQ:MEDP) has increased a share buyback program by $50M. In March, the company's board approved a $200M increase to the program. At the end of Q1 2022, Medpace (MEDP) had had $264.6M remaining. Seeking Alpha contributor Samuel Eneh says the repurchases are a sig...
Wasatch Global Investors is a comprehensive small-cap equity manager singularly focused on delivering superior risk-adjusted returns for our clients. If we don’t perceive macro events as impacting long-term company fundamentals, our response is to stay the course. During th...
Guggenheim has initiated coverage of five contract research organizations (CROs) and recommends three -- ICON plc (NASDAQ:ICLR), IQVIA Holdings (NYSE:IQV), and Syneos Health (NASDAQ:SYNH) -- as buys. The firm sees the greatest upside -- 32% -- with ICON (ICLR) based on a target price of $285....
Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. A broad-based selling of risk assets, high correlations and a preference for the types of companies that typically do not meet our inv...
Clinical stage pharma company Citius Pharmaceuticals (NASDAQ:CTXR) announced on Friday that it has selected the clinical research organization (CRO), Biorasi, to assist in the expansion of its Phase 3 Mino-Lok trial to additional sites outside the U.S. The pivotal trial is an open-label rando...
No Rating Change. Medpace remains an attractive business selling at a discount to its intrinsic value. Management is aggressively repurchasing shares, a signal of confidence and a boost to EPS. For further details see: Medpace Holdings: Update Following Q1 FY2022 Earning...
Medpace Holdings, Inc. (MEDP) Q1 2022 Earnings Conference Call April 26, 2022 9:00 AM ET Company Participants Lauren Morris – Director-Investor Relations August Troendle – Chief Executive Officer Jesse Geiger – President Kevin Brady – Chief Financial Officer Confer...
Image source: The Motley Fool. Medpace Holdings, Inc. Common Stock (NASDAQ: MEDP) Q1 2022 Earnings Call Apr 26, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: Medpace Holdings, Inc. Common Stock (MEDP) Q1 2022 Earn...
News, Short Squeeze, Breakout and More Instantly...
Medpace Holdings Inc. Company Name:
MEDP Stock Symbol:
NASDAQ Market:
Medpace Holdings Inc. Website:
Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease ...
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...